Syndax Pharmaceuticals
SNDX
66 hedge funds and large institutions have $219M invested in Syndax Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 30 increasing their positions, 13 reducing their positions, and 10 closing their positions.
131% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 13
37% more capital invested
Capital invested by funds: $160M → $219M (+$59.5M)
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
7.5% more ownership
Funds ownership: 63.89% → 71.39% (+7.5%)
5% more funds holding
Funds holding: 63 → 66 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$10.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.13M |
| 3 |
Millennium Management
New York
|
+$5.3M |
| 4 |
JP Morgan Chase
New York
|
+$4.97M |
| 5 |
BlackRock
New York
|
+$4.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.36M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$824K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$686K |
| 5 |
O
OrbiMed
New York
|
-$546K |
SNDX Hedge Fund Activity: Q2 2017 in Review
66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2017, worth a combined $219M — up 37% from $160M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SNDX positions and 10 closed out — a net gain of 3 holders — while 30 added to existing stakes and 13 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $10.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.3M sold.
- 66 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2017, up from 63 in Q1 2017.
- Funds reported $219M of Syndax Pharmaceuticals stock for Q2 2017, up 37% quarter-over-quarter.
- 13 funds opened new Syndax Pharmaceuticals positions in Q2 2017 and 10 closed out, a net change of +3 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2017 was Jennison Associates, an estimated $10.9M added.
- The largest Syndax Pharmaceuticals seller in Q2 2017 was Cormorant Asset Management, an estimated $3.3M sold.
Based on aggregated 13F filings for Q2 2017.